Related Experiment Videos
Treating allergic rhinitis in pregnancy. Safety considerations.
P Mazzotta1, R Loebstein, G Koren
1Motherisk Program, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, University of Toronto, Ontario, Canada.
Drug Safety
|May 7, 1999
Summary
Pregnant women with allergic rhinitis can safely use many medications. Review of evidence shows most treatments pose no risk to fetal development, allowing effective symptom management.
Area of Science:
- Obstetrics and Gynecology
- Allergology
- Pharmacology
Background:
- Allergic rhinitis affects many women of childbearing age, necessitating treatment during pregnancy.
- Current product labels often advise against medication use due to limited fetal safety data, despite available human evidence.
- This review critically examines the literature on pharmacotherapy for allergic rhinitis in pregnancy.
Observation:
- Immunotherapy, intranasal sodium cromoglycate (cromolyn), and beclomethasone are recommended first-line treatments due to safety and efficacy.
- First-generation antihistamines (e.g., chlorpheniramine) are favored over second-generation due to more extensive safety data.
- Decongestants are second-line options, requiring further safety studies; data on specific antihistamines and intranasal corticosteroids in pregnancy is limited.
Findings:
- Most medications for allergic rhinitis have human data refuting concerns about fetal teratogenicity.
- Evidence supports the use of immunotherapy, cromolyn, beclomethasone, and certain antihistamines during pregnancy.
- Further research is needed for decongestants and newer antihistamines/corticosteroids.
Implications:
- Pregnant women with allergic rhinitis can be effectively treated with available medications.
- Treatment choices should balance fetal safety evidence with therapeutic efficacy.
- This review provides guidance for managing allergic rhinitis in pregnant patients, challenging existing contraindications.